Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy

Angelo Antonini, Patrizia Berto, Stefania Lopatriello, Filippo Tamma, Lieven Annemans, Mike Chambers

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Economic evaluation (Italian NHS perspective) modeling 123I-FP-CIT SPECT (DaTSCAN®) compared to clinical judgment alone for differentiating essential tremor (ET) from Parkinson's Disease (PD). A 5-year Markov model was constructed to assess the cost-effectiveness of 123I-FP-CIT SPECT to differentiate ET from PD in patients referred to a movement disorder specialist in Italy. Published data and a double-round, Delphi panel of 12 specialists populated the model. Effectiveness was expressed as the projected Years on potentially beneficial therapy (PBTYs). Costs were expressed in Euros (2005 values). The model suggests that over 5 years, the "current" diagnostic pathway generated an average of 2.3 PBTYs/patient at an estimated cost of €8,864. 123I-FP-CIT SPECT generated an average of 4.1 PBTYs/patient at an estimated cost of €8,422, which represented an additional 1.8 PBTYs at a cost saving of €442/patient (€341 when discounted at 5%). The estimated cost-effectiveness of 123I-FP-CIT SPECT is under €1,000 per PBTY gained when the underlying disease prevalence is high (55-70%), and cost-saving at prevalence under 55%. 123I-FP-CIT SPECT is likely to be regarded as economically advantageous to differentiate ET from PD, increasing time on potentially beneficial therapy at a lower overall cost to the healthcare system.

Original languageEnglish
Pages (from-to)2202-2209
Number of pages8
JournalMovement Disorders
Volume23
Issue number15
DOIs
Publication statusPublished - Nov 15 2008

Fingerprint

Essential Tremor
Single-Photon Emission-Computed Tomography
Italy
Cost-Benefit Analysis
Parkinson Disease
Differential Diagnosis
Costs and Cost Analysis
Therapeutics
Movement Disorders
2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane
Delivery of Health Care

Keywords

  • I-FP-CIT
  • Cost-effectiveness
  • DaTSCAN®
  • Essential tremor
  • Parkinson's disease
  • Parkinsonism
  • Single photon emission computed tomography (SPECT)

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. / Antonini, Angelo; Berto, Patrizia; Lopatriello, Stefania; Tamma, Filippo; Annemans, Lieven; Chambers, Mike.

In: Movement Disorders, Vol. 23, No. 15, 15.11.2008, p. 2202-2209.

Research output: Contribution to journalArticle

Antonini, A, Berto, P, Lopatriello, S, Tamma, F, Annemans, L & Chambers, M 2008, 'Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy', Movement Disorders, vol. 23, no. 15, pp. 2202-2209. https://doi.org/10.1002/mds.22278
Antonini, Angelo ; Berto, Patrizia ; Lopatriello, Stefania ; Tamma, Filippo ; Annemans, Lieven ; Chambers, Mike. / Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. In: Movement Disorders. 2008 ; Vol. 23, No. 15. pp. 2202-2209.
@article{cad19880fa0c4d56a444784c0e7a1090,
title = "Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy",
abstract = "Economic evaluation (Italian NHS perspective) modeling 123I-FP-CIT SPECT (DaTSCAN{\circledR}) compared to clinical judgment alone for differentiating essential tremor (ET) from Parkinson's Disease (PD). A 5-year Markov model was constructed to assess the cost-effectiveness of 123I-FP-CIT SPECT to differentiate ET from PD in patients referred to a movement disorder specialist in Italy. Published data and a double-round, Delphi panel of 12 specialists populated the model. Effectiveness was expressed as the projected Years on potentially beneficial therapy (PBTYs). Costs were expressed in Euros (2005 values). The model suggests that over 5 years, the {"}current{"} diagnostic pathway generated an average of 2.3 PBTYs/patient at an estimated cost of €8,864. 123I-FP-CIT SPECT generated an average of 4.1 PBTYs/patient at an estimated cost of €8,422, which represented an additional 1.8 PBTYs at a cost saving of €442/patient (€341 when discounted at 5{\%}). The estimated cost-effectiveness of 123I-FP-CIT SPECT is under €1,000 per PBTY gained when the underlying disease prevalence is high (55-70{\%}), and cost-saving at prevalence under 55{\%}. 123I-FP-CIT SPECT is likely to be regarded as economically advantageous to differentiate ET from PD, increasing time on potentially beneficial therapy at a lower overall cost to the healthcare system.",
keywords = "I-FP-CIT, Cost-effectiveness, DaTSCAN{\circledR}, Essential tremor, Parkinson's disease, Parkinsonism, Single photon emission computed tomography (SPECT)",
author = "Angelo Antonini and Patrizia Berto and Stefania Lopatriello and Filippo Tamma and Lieven Annemans and Mike Chambers",
year = "2008",
month = "11",
day = "15",
doi = "10.1002/mds.22278",
language = "English",
volume = "23",
pages = "2202--2209",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "15",

}

TY - JOUR

T1 - Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy

AU - Antonini, Angelo

AU - Berto, Patrizia

AU - Lopatriello, Stefania

AU - Tamma, Filippo

AU - Annemans, Lieven

AU - Chambers, Mike

PY - 2008/11/15

Y1 - 2008/11/15

N2 - Economic evaluation (Italian NHS perspective) modeling 123I-FP-CIT SPECT (DaTSCAN®) compared to clinical judgment alone for differentiating essential tremor (ET) from Parkinson's Disease (PD). A 5-year Markov model was constructed to assess the cost-effectiveness of 123I-FP-CIT SPECT to differentiate ET from PD in patients referred to a movement disorder specialist in Italy. Published data and a double-round, Delphi panel of 12 specialists populated the model. Effectiveness was expressed as the projected Years on potentially beneficial therapy (PBTYs). Costs were expressed in Euros (2005 values). The model suggests that over 5 years, the "current" diagnostic pathway generated an average of 2.3 PBTYs/patient at an estimated cost of €8,864. 123I-FP-CIT SPECT generated an average of 4.1 PBTYs/patient at an estimated cost of €8,422, which represented an additional 1.8 PBTYs at a cost saving of €442/patient (€341 when discounted at 5%). The estimated cost-effectiveness of 123I-FP-CIT SPECT is under €1,000 per PBTY gained when the underlying disease prevalence is high (55-70%), and cost-saving at prevalence under 55%. 123I-FP-CIT SPECT is likely to be regarded as economically advantageous to differentiate ET from PD, increasing time on potentially beneficial therapy at a lower overall cost to the healthcare system.

AB - Economic evaluation (Italian NHS perspective) modeling 123I-FP-CIT SPECT (DaTSCAN®) compared to clinical judgment alone for differentiating essential tremor (ET) from Parkinson's Disease (PD). A 5-year Markov model was constructed to assess the cost-effectiveness of 123I-FP-CIT SPECT to differentiate ET from PD in patients referred to a movement disorder specialist in Italy. Published data and a double-round, Delphi panel of 12 specialists populated the model. Effectiveness was expressed as the projected Years on potentially beneficial therapy (PBTYs). Costs were expressed in Euros (2005 values). The model suggests that over 5 years, the "current" diagnostic pathway generated an average of 2.3 PBTYs/patient at an estimated cost of €8,864. 123I-FP-CIT SPECT generated an average of 4.1 PBTYs/patient at an estimated cost of €8,422, which represented an additional 1.8 PBTYs at a cost saving of €442/patient (€341 when discounted at 5%). The estimated cost-effectiveness of 123I-FP-CIT SPECT is under €1,000 per PBTY gained when the underlying disease prevalence is high (55-70%), and cost-saving at prevalence under 55%. 123I-FP-CIT SPECT is likely to be regarded as economically advantageous to differentiate ET from PD, increasing time on potentially beneficial therapy at a lower overall cost to the healthcare system.

KW - I-FP-CIT

KW - Cost-effectiveness

KW - DaTSCAN®

KW - Essential tremor

KW - Parkinson's disease

KW - Parkinsonism

KW - Single photon emission computed tomography (SPECT)

UR - http://www.scopus.com/inward/record.url?scp=57749208525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57749208525&partnerID=8YFLogxK

U2 - 10.1002/mds.22278

DO - 10.1002/mds.22278

M3 - Article

C2 - 18785639

AN - SCOPUS:57749208525

VL - 23

SP - 2202

EP - 2209

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 15

ER -